Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
AssigneeTrustees of Boston University
InventorsAvrum Spira, Marc Lenburg, Joseph Perez-Rogers, Christina Anderlind
Life of this patent
Estimating the term…
Abstract
Disclosed herein are assays and methods for diagnosis and prognosis of lung cancer using expression analysis of one or more genes from a biological sample comprising nasal epithelial cells. The assays and methods of the invention provide non-invasive means of accurately detecting the presence or absence of lung cancer relative to, for example, more invasive techniques, such as bronchoscopy. Similarly, in certain aspects, the assays and methods disclosed herein provide non-invasive means of accurately identifying the smoking history of a subject.
Claims87
A method of diagnosing lung cancer in a subject comprising the steps of:
- (a) measuring a biological sample comprising nasal epithelial cells of the subject for expression of one or more genes;
- and (b) comparing the expression of the one or more genes to a control sample of those genes from individuals without cancer;
- wherein the one or more genes are selected from the group consisting of genes in Table 12, Table 13 or Table 21, and wherein differential expression of the subject's one or more genes relative to the control sample is indicative of the subject having lung cancer.
A method of diagnosing lung cancer in a subject comprising the steps of:
- (a) measuring a biological sample comprising nasal epithelial cells of the subject for expression of one or more genes;
- and (b) comparing the expression of the one or more genes to a control sample of those genes from individuals with cancer;
- wherein the one or more genes are selected from the group consisting of genes in Table 12, Table 13 or Table 21, and wherein differential expression of the subject's one or more genes relative to the control sample is indicative of the subject not having lung cancer.
A method of determining whether a subject has quit smoking comprising the steps of:
- (a) measuring a biological sample comprising nasal epithelial cells of the subject for expression of one or more genes selected from the group consisting of genes in Table 5 or Table 6;
- and (b) comparing the expression of the one or more genes to a control sample of those genes from non-smokers;
- wherein altered expression of the subject's genes relative to the control sample is indicative of the subject having quit smoking.
A method of determining whether a subject has quit smoking comprising the steps of:
- (a) measuring a biological sample comprising nasal epithelial cells of the subject for expression of one or more genes selected from the group consisting of genes in Table 5 or Table 6;
- and (b) comparing the expression of the one or more genes to a control sample of those genes from smokers;
- wherein altered expression of the subject's genes relative to the control sample is indicative of the subject not having quit smoking.
A method of determining the likelihood that a subject has lung cancer, the method comprising:
- (a) subjecting a biological sample comprising nasal epithelial cells to a gene expression analysis, wherein the gene expression analysis comprises comparing gene expression levels of one or more genes selected from the group of genes in Table 12, Table 13 or Table 21 to the expression levels of a control sample of those genes from individuals without cancer;
- and (b) determining the likelihood that the subject has lung cancer by determining differential expression of the subject's one or more genes relative to the group of genes in Table 12, Table 13 or Table 21, wherein differential expression of the subject's genes relative to the control sample is indicative of the subject having a high likelihood of lung cancer.
A method of determining the likelihood that a subject has lung cancer, the method comprising:
- (a) subjecting a biological sample comprising nasal epithelial cells to a gene expression analysis, wherein the gene expression analysis comprises comparing gene expression levels of one or more genes selected from the group of genes in Table 12, Table 13 or Table 21 to the expression levels of a control sample of those genes from individuals with cancer;
- and (b) determining the likelihood that the subject has lung cancer by determining differential expression of the subject's one or more genes relative to the group of genes in Table 12, Table 13 or Table 21, wherein differential expression of the subject's genes relative to the control sample is indicative of the subject having a low likelihood of lung cancer.
A composition comprising one or more nucleic acid probes, wherein each of the one or more nucleic acids probes specifically hybridizes with an mRNA expressed from five or more genes selected from the group of genes in Table 5, Table 6, Table 12, Table 13 or Table 21.
A minimally-invasive method of determining the likelihood that a subject does not have lung cancer, the method comprising:
- (a) detecting, by quantitative reverse transcription polymerase chain reaction, a bead-based nucleic acid detection assay or a oligonucleotide array assay, mRNA or cDNA expression levels in a sample comprising nasal epithelial cells from a subject;
- (b) determining mRNA or cDNA expression levels in the sample of nasal epithelial cells of two or more gene selected from the group consisting of the genes in Table 12, Table 13 or Table 21;
- and
- (c) based on the expression levels determined in (b), determining a lung cancer risk-score that is indicative of the likelihood that the subject does not have lung cancer.
Dependencies are inferred from the claim text.